Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance
Executive Summary
HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.
You may also be interested in...
From Treatment To Prevention To A Cure: An Interview With Gilead’s HIV R&D Leaders
Gilead execs Jared Baeten and Tomas Cihlar talk to Scrip about how the company, still the leader in HIV, is working toward less-frequent dosing, providing PrEP for broader populations and maybe finding a cure for HIV infection.
ViiV Thinks It May Get All-Gender Approval For Cabotegravir For PrEP
Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.
ViiV Thinks It May Get All-Gender Approval For Cabotegravir For PrEP
Final data comparing cabotegravir to Truvada for HIV prophylaxis confirms superiority. ViiV says treatment data in women may enable an all-gender approval that eluded Gilead with Descovy.